IL208940A0 - Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis - Google Patents

Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis

Info

Publication number
IL208940A0
IL208940A0 IL208940A IL20894010A IL208940A0 IL 208940 A0 IL208940 A0 IL 208940A0 IL 208940 A IL208940 A IL 208940A IL 20894010 A IL20894010 A IL 20894010A IL 208940 A0 IL208940 A0 IL 208940A0
Authority
IL
Israel
Prior art keywords
compositions
treatment
recombinant human
nasal rhinitis
rhinitis
Prior art date
Application number
IL208940A
Other languages
English (en)
Original Assignee
Clarassance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarassance Inc filed Critical Clarassance Inc
Publication of IL208940A0 publication Critical patent/IL208940A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL208940A 2008-05-13 2010-10-26 Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis IL208940A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5286108P 2008-05-13 2008-05-13
PCT/US2009/043613 WO2009140269A2 (en) 2008-05-13 2009-05-12 Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis

Publications (1)

Publication Number Publication Date
IL208940A0 true IL208940A0 (en) 2011-01-31

Family

ID=41319290

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208940A IL208940A0 (en) 2008-05-13 2010-10-26 Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis

Country Status (12)

Country Link
US (3) US20110240012A1 (enExample)
EP (2) EP3085382A1 (enExample)
JP (1) JP5773437B2 (enExample)
KR (1) KR20110014199A (enExample)
CN (1) CN102292099A (enExample)
AU (1) AU2009246543B2 (enExample)
BR (1) BRPI0911945A2 (enExample)
CA (1) CA2724277A1 (enExample)
IL (1) IL208940A0 (enExample)
MX (1) MX2010012234A (enExample)
NZ (2) NZ600803A (enExample)
WO (1) WO2009140269A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
CN102292099A (zh) 2008-05-13 2011-12-21 科拉森斯公司 在鼻炎治疗中使用的重组人cc10及其组合物
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
EP2488205B1 (en) * 2009-10-15 2016-09-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
WO2012170842A2 (en) 2011-06-09 2012-12-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide for protection of allergic respiratory disorders
CA2928035C (en) 2012-12-27 2024-07-02 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
PE20200404A1 (es) * 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
WO2016205430A1 (en) * 2015-06-15 2016-12-22 Therabron Therapeutics, Inc. Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke
JP7085485B2 (ja) 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー 分泌型ｐ－糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである
CN113543827B (zh) * 2019-02-27 2025-01-21 奥蒂卡拉股份有限公司 用于治疗鼻、鼻腔鼻窦和鼻咽组织感染和/或炎症的方法
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US12295933B2 (en) 2019-03-25 2025-05-13 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691009A (en) 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
WO1987002367A2 (en) 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5266562A (en) 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5354269A (en) 1991-12-20 1994-10-11 Fibrogenex, Inc. Method for treating cancer resections
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5482930A (en) 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
US5470885A (en) 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
FR2724665B1 (fr) 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5696092A (en) 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
WO1997001627A1 (en) 1995-06-27 1997-01-16 Igen International, Inc. High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
WO1997034997A1 (en) 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
AU5253998A (en) 1996-11-13 1998-06-03 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20020160948A1 (en) * 1998-07-21 2002-10-31 Aprile Pilon Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20030207795A1 (en) 1997-05-28 2003-11-06 Pilon Aprile L. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060025348A1 (en) 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US6255281B1 (en) 1997-05-28 2001-07-03 Claragen, Inc. And U.S. Government Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20050261180A1 (en) 1997-05-28 2005-11-24 Pilon Aprile L Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20020169108A1 (en) 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
JP4949552B2 (ja) 1998-04-16 2012-06-13 エンサイシブ・フアーマシユーテイカルズ，インコーポレイテツド インテグリンのそれの受容体への結合を阻害するｎ，ｎ−ジ置換アミド
WO2000072868A2 (en) 1999-06-01 2000-12-07 Prendergast Patrick T Peptides for therapeutic use
AU1582401A (en) 1999-11-04 2001-05-14 Human Genome Sciences, Inc. Uteroglobin-like polynucleotides, polypeptides, and antibodies
CA2405946A1 (en) 2000-04-14 2001-10-25 Claragen, Inc. Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production
US20020025510A1 (en) 2000-07-26 2002-02-28 Strongin Alex Y. Screening methods based on superactivated alpha V beta 3 integrin
WO2003057257A1 (en) * 2002-01-02 2003-07-17 The Johns Hopkins University Cc10 inhibits th2 cytokines and eotaxins involved in allergic diseases
US20090227025A1 (en) 2003-06-06 2009-09-10 The Board Of Regents Of The University Of Texas System Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism
EP1789067B8 (en) * 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
EP2086560A4 (en) * 2006-11-02 2012-03-28 Riolan Technologies Inc METHODS OF TREATING EPIPHORA
EP1935242A1 (en) * 2006-12-21 2008-06-25 Philip Morris Products S.A. Transgenic animal model
WO2009126623A2 (en) 2008-04-08 2009-10-15 Amyris Biotechnologies, Inc. Expression of heterologous sequences
CN102292099A (zh) 2008-05-13 2011-12-21 科拉森斯公司 在鼻炎治疗中使用的重组人cc10及其组合物
EP2488205B1 (en) 2009-10-15 2016-09-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza

Also Published As

Publication number Publication date
WO2009140269A2 (en) 2009-11-19
AU2009246543A1 (en) 2009-11-19
AU2009246543B2 (en) 2015-08-06
US9844580B2 (en) 2017-12-19
US20180125931A1 (en) 2018-05-10
EP2303308A4 (en) 2012-11-07
CN102292099A (zh) 2011-12-21
KR20110014199A (ko) 2011-02-10
JP5773437B2 (ja) 2015-09-02
US20160158315A1 (en) 2016-06-09
JP2011520894A (ja) 2011-07-21
CA2724277A1 (en) 2009-11-19
EP2303308A2 (en) 2011-04-06
BRPI0911945A2 (pt) 2015-10-13
WO2009140269A3 (en) 2011-10-27
NZ600803A (en) 2013-12-20
MX2010012234A (es) 2011-03-03
NZ588895A (en) 2012-07-27
US20110240012A1 (en) 2011-10-06
EP3085382A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
IL208940A0 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
EP2102237A4 (en) RECOMBINANT HUMAN FACTOR IX AND USE THEREOF
PL2254869T3 (pl) Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40
IL202684A0 (en) Anti-cd20 therapeutic compositions and methods of use thereof
IL259547B (en) Isolated protein and preparations containing it for use in the treatment of disorders caused by il-1
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
AP2965A (en) Therapeutic compositions and the use thereof
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
AP2490A (en) Therapeutic compositions and the use thereof
EP2205236A4 (en) NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
ZA201202151B (en) Compositions comprising tramadol and celecoxib in the treatment of pain
IL211459A0 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
ZA201007091B (en) Vaccine compositions for the treatment of dengue fever and uses thereof
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0908868D0 (en) Depsipeptide and their therapeutic use
ZA201001207B (en) Therapeutic formulations for the treatment of cold and flu-like symptoms
HUE047515T2 (hu) N-Szubsztituált benzolpropánamidok fájdalom és gyulladás kezelésében történõ alkalmazásra
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL214353A0 (en) Dimeric pyrrolopyrimidinedione and its use in therapy of respiratory diseases
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
PL2421520T3 (pl) ALBUMINA i/lub MANNITOL DO LECZENIA POLIPÓW NOSA
GB0821383D0 (en) Compositions for use in the treatment of dry eye and methods based thereon